Instrument Inactif

Communiqués Elite Pharmaceuticals, Inc. Other OTC

Actions

ELTP

US28659T2006

Produits pharmaceutiques

Communiqués

13/08	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information	NE
10/08	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026	NE
04/08	Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL	NE
29/06	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information	NE
23/06	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026	NE
15/06	Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study	NE
01/06	Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product	NE
02/04	Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets	NE
18/02	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 and Provides Conference Call Information	AQ
17/02	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information	NE
11/02	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026	NE
14/11	Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information	NE
12/11	Elite Pharmaceuticals Receives FDA Approval for Generic Requip XL(R)	NE
10/11	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025	NE
14/08/25	Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call Information	NE
08/08/25	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025	NE
30/06/25	Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2025 and Provides Conference Call Information	NE
23/06/25	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025	NE
16/06/25	Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study	NE
30/04/25	Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets	NE
03/03/25	Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line	NE
13/02/25	Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information	NE
10/02/25	Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025	NE
26/12/24	Elite Pharmaceuticals : Announces Commercial Launch of Generic Vyvanse® Form 8 K	PU
26/12/24	Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)	NE